4 recruiting, 2 not yet recruiting, 1 enrolling by invitation, 1 terminated. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 4, Not yet recruiting 2, Enrolling by invitation 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Solid Tumors (Phase 1): new trials by email Literature Review of Solid Tumors (Phase 1) trials Research Report on Solid Tumors (Phase 1)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MTX-531-001 Phase 1 Study in Advanced Solid Tumors MTX-531 - Solid Tumors (Phase 1), HNSCC | Phase 1 | Not yet recruiting | MEKanistic Therapeutics, Inc. | 71 | 2026-10-20 | 2026-10-15 |
| First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors ADCE-B05 - Solid Tumors (Phase 1) | Phase 1 | Recruiting | Adcendo ApS | 180 | 2026-03-17 | 2026-07-24 |
| Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation HSK42360-Na - Solid Tumors (Phase 1) | Phase 1 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 159 | 2026-03-06 | 2026-05-01 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations AN9025 oral capsule - Solid Tumors (Phase 1), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 118 | 2026-01-28 | 2026-06-08 |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
| A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors ABSK131 - Solid Tumors (Phase 1) | Phase 1 | Recruiting | Abbisko Therapeutics Co, Ltd | 266 | 2025-07-22 | 2025-12-17 |
| Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors AROG4-01 - Solid Tumors (Phase 1), Mesothelioma | Phase 1 | Not yet recruiting | Aromics Therapeutics | 35 | 2025-01-01 | 2024-11-07 |
| Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) USL311, Lomustine - Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2) | Phase 1 / Phase 2 | Terminated | Proximagen, LLC | 26 | 2016-04-01 | 2021-07-23 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Glioblastoma (1) · Mesothelioma (1) · Ovarian Neoplasms (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Bronchial Neoplasms (2)
Lomustine (1) · pembrolizumab (1)
Abbisko Therapeutics Co, Ltd (1) · Adcendo ApS (1) · Adlai Nortye Biopharma Co., Ltd. (1) · Aromics Therapeutics (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · MEKanistic Therapeutics, Inc. (1) · Proximagen, LLC (1) · Rondo Therapeutics (1)
United States (5) · China (2) · Australia (1) · Spain (1)
Thomas Manley, MD (1) · Tze-Chiang Meng, MD (1)